Shorts

0:50

Don't Over-Treat Based on Risk Scores

3 months ago

Rami Komrokji, MD

0:17

Targeted: On Location at Memorial Sloan Kettering Cancer Center

3 months ago

Helena Yu, MD(+2 more)

0:42

Understanding MDS Staging and the Path to Cure

3 months ago

Rami Komrokji, MD

0:49

ctDNA & MRD: Smarter Therapy Decisions in Metastatic GE Cancer

3 months ago

Rutika Mehta, MD, MPH

0:46

Combining CELMoDs and Cell Therapies in Myeloma

3 months ago

Sagar Lonial, MD, FACP

0:49

Balancing Therapy and QOL With MRD Testing in Gastroesophageal Cancer

3 months ago

Rutika Mehta, MD, MPH

0:35

A Mass in the Right-Sided Kidney

3 months ago

Pavlos Msaouel, MD, PhD

0:47

Menin Inhibitors Could Redefine AML Frontline Therapy

3 months ago

Richard Stone, MD

0:42

Setting a New Standard in EGFR+ Lung Cancer

3 months ago

Nicolas Girard, MD, PhD

0:46

Survival With Bispecific Combo Favors Early Use in Myeloma

3 months ago

Roberto Mina, MD

0:33

The Key Test to Confirm RMC Diagnosis is Immunohistochemistry for INI1

3 months ago

Pavlos Msaouel, MD, PhD

0:48

The Need for HRR Mutation Testing in Prostate Cancer

3 months ago

Sandy Srinivas, MD

1:27

Are We Nearing the End of 7+3 Alone in AML?

3 months ago

Richard Stone, MD

0:32

One Analogy Doesn't Work for Every Patient

3 months ago

Sanjay K. Juneja, MD(+1 more)

0:34

Managing Toxicities in Patients on Erdafitinib Therapy

3 months ago

Thomas W. Flaig, MD

0:59

The Power of a Gut Feeling in Cancer Care

3 months ago

Sanjay K. Juneja, MD

0:38

New Frontiers in Urothelial Carcinoma

3 months ago

Thomas W. Flaig, MD

0:32

CLL17 3-Year Update: Who May Benefit From Continuous Therapy?

3 months ago

Nicole Lamanna, MD

1:00

Bringing Clinical Trials Into the Community

3 months ago

Danny Nguyen, MD

0:43

Early-Onset CRC: Thinking Beyond the Tumor

3 months ago

Patrick Boland, MD

0:46

How AI is Revolutionizing Clinical Trials

3 months ago

Danny Nguyen, MD

0:57

Why Clinical Trials Aren't Just a Last Resort for Cancer

3 months ago

Danny Nguyen, MD

0:55

Big Shifts Ahead in Lung Cancer: New KRAS Data and Paradigm Changes

3 months ago

Christine Bestvina, MD

0:28

Decentralized Clinical Trials: Reducing the Logistical Burden of Participation

3 months ago

Inna Gong, MD, PhD

1:18

Why Women Face Longer Delays in Lung Cancer Diagnosis

3 months ago

Narjust Florez, MD

0:57

A “Cancer Genome Atlas” for Immune Profiles?

3 months ago

Won Jin Ho, MD

0:32

Confronting Feelings of Guilt in Younger Patients

3 months ago

Narjust Florez, MD

0:51

Why Young Women's Lung Cancer Symptoms Are Often Ignored

3 months ago

Narjust Florez, MD

1:07

Why ZIP Code Shouldn't Determine Cancer Outcomes

3 months ago

Pallav K. Mehta, MD(+1 more)

0:52

Guideline Updates in Lymphoma Treatment

3 months ago

Hua-Jay "Jeff" Cherng, MD

Shorts

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC

Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC

How a Virtual Behavioral Health Program Is Reaching Patients With Cancer Who Need It Most

Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy

Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care